Savient Pharmaceuticals, Inc. announced that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for KRYSTEXXAT (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated. The resubmission includes data from three consecutive manufacturing validation batches of the pegloticase active pharmaceutical ingredient (API) drug substance, additional and improved analytical methods for the control and release of pegloticase API and KRYSTEXXA and other data which are designed to address the issues cited by the FDA in its July 31 2009 Complete Response Letter (CRL). It also includes a Safety Update from the remaining studies that were ongoing at the time of the previous 120-Day Safety Update. Additional documents included in the resubmission are proposals for product labeling and prescribing information, REMS program materials and a patient Medication Guide, all of which were requested in the CRL and the Company believes are consistent with previous discussions with the FDA associated with the Company's September 14, 2009 Type A meeting.

Savient Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2009. The net loss for the fourth quarter of 2009 was $0.2 million, or $0.00 per basic and diluted share, on total revenues of $0.9 million, compared with a net loss of $24.2 million, or $0.45 per basic and diluted share, on total revenues of $1.1 million for the fourth quarter of 2008. Significantly offsetting the net loss for the three months ended December 31, 2009 is a non-cash gain of $12.4 million due to a valuation adjustment relating to warrants that issued in connection with the April 2009 registered direct offering. On a non-Generally Accepted Accounting Principles (GAAP) basis, excluding the $12.4 million valuation adjustment, the net loss for the fourth quarter of 2009 was $12.6 million, or $0.19 per basic and diluted share, compared with a GAAP net loss for the fourth quarter of 2008 of $24.2 million, or $0.45 per basic and diluted share. The decrease in revenue was due to lower net product sales of the authorized generic oxandrolone product due to increased generic competition. Non-GAAP net Loss was $12.6 million or $0.19 per basic and diluted share as compared to $24.2 million $0.45 per basic and diluted share for the same period prior year. The net loss for the year ended December 31, 2009 was $90.9 million, or $1.51 per basic and diluted share, on total revenues of $3.0 million, compared with a net loss of $84.2 million, or $1.57 per basic and diluted share, on total revenues of $3.2 million for the same period in 2008. The net loss for the year ended December 31, 2009 includes a non-cash charge of $11.7 million due to a valuation adjustment relating to warrants that issued in connection with April 2009 registered direct offering. On a non-GAAP basis, excluding the $11.7 million non-cash charge, the net loss for the year ended December 31, 2009 was $79.2 million, or $1.32 per basic and diluted share, compared with a GAAP net loss of $84.2 million for the year ended December 31, 2008, or $1.57 per basic and diluted share. The decrease in revenue resulted primarily from lower net product sales of OxandrinR and the authorized generic oxandrolone product due to increased generic competition. Non-GAAP net Loss was $79.2 million $1.32 per basic and diluted share as compared to $84.2 million $1.57 per basic and diluted share for the same period prior year.

Savient Pharmaceuticals, Inc. expected to Report Q1 2010 Results on May 3, 2010. This event was calculated by Capital IQ (Created on February 26, 2010).

Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy

SAVIENT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a

Savient posts smaller loss due to warrant gain

Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results

Savient to Present at the Cowen and Company 30th Annual Health Care Conference

Savient posts smaller loss due to warrant gain

Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results

Savient to Present at the Cowen and Company 30th Annual Health Care Conference

Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010

Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010

SAVIENT PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits

Savient Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference

Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results

Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities

Savient To Present at the 28th Annual JP Morgan Healthcare Conference

Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities

Savient To Present at the 28th Annual JP Morgan Healthcare Conference

SAVIENT PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits

Savient Pharmaceuticals to Hold Third Quarter 2009 Financial Results Conference Call on Thursday, November 5, 2009

Savient Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference